MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

Search

Novo Nordisk A-S

Deschisă

SectorSănătate

68.51 -0.09

Rezumat

Modificarea prețului

24h

Curent

Minim

68.18

Maxim

69.9

Indicatori cheie

By Trading Economics

Venit

929M

28B

Vânzări

14B

86B

P/E

Medie Sector

22.897

73.239

EPS

6.34

Randament dividend

2.15

Marjă de profit

32.947

Angajați

76,302

EBITDA

4.2B

40B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+47.43% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.15%

3.06%

Statistici piață

By TradingEconomics

Capitalizare de piață

51B

336B

Deschiderea anterioară

68.6

Închiderea anterioară

68.51

Sentimentul știrilor

By Acuity

20%

80%

38 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Novo Nordisk A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 feb. 2025, 15:33 UTC

Principalele dinamici ale pieței

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 feb. 2025, 11:53 UTC

Câștiguri

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 feb. 2025, 08:19 UTC

Câștiguri

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

31 mar. 2025, 12:49 UTC

Market Talk

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28 mar. 2025, 15:11 UTC

Market Talk

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 mar. 2025, 13:45 UTC

Market Talk
Câștiguri

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 mar. 2025, 10:19 UTC

Market Talk

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 mar. 2025, 09:08 UTC

Market Talk
Câștiguri

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 mar. 2025, 15:54 UTC

Top știri

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 mar. 2025, 15:31 UTC

Market Talk

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 mar. 2025, 14:58 UTC

Market Talk

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 feb. 2025, 12:00 UTC

Top știri

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb. 2025, 10:30 UTC

Top știri

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb. 2025, 16:16 UTC

Top știri
Câștiguri

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb. 2025, 14:56 UTC

Câștiguri

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 feb. 2025, 13:59 UTC

Câștiguri

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 feb. 2025, 12:02 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb. 2025, 11:35 UTC

Market Talk
Câștiguri

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 feb. 2025, 10:10 UTC

Acțiuni populare

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 feb. 2025, 09:43 UTC

Câștiguri

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb. 2025, 08:47 UTC

Market Talk
Câștiguri

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 feb. 2025, 08:38 UTC

Market Talk
Câștiguri

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 feb. 2025, 08:32 UTC

Câștiguri

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb. 2025, 08:30 UTC

Market Talk
Câștiguri

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 feb. 2025, 06:46 UTC

Câștiguri

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 feb. 2025, 06:45 UTC

Câștiguri

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5 feb. 2025, 06:43 UTC

Câștiguri

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

5 feb. 2025, 06:42 UTC

Câștiguri

Novo Nordisk: 2025 Capex Expected to be Around DKK65B, Reflecting Expansion of Global Supply Chain

5 feb. 2025, 06:39 UTC

Câștiguri

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints and Related Drug Shortage Notifications

Comparație

Modificare preț

Novo Nordisk A-S Așteptări

Obiectiv de preț

By TipRanks

47.43% sus

Prognoză pe 12 luni

Medie 102.17 USD  47.43%

Maxim 124 USD

Minim 90 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

5

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 80.15Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

38 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.